To unlock this feature and to subscribe to our weekly evidence emails, please create a FREE orthoEvidence account.

SIGNUP

Already Have an Account?

Loading...
Visit our Evidence-Based Covid-19 Website and Stay Up to Date with the latest Research.
Ace Report Cover

Tanezumab in Japanese patients with moderate to severe osteoarthritis of the knee

Download
Share
Reprints
Cite This
About
+ Favorites
Share
Reprints
Cite This
About
+ Favorites
Author Verified
Ace Report Cover
August 2013

Tanezumab in Japanese patients with moderate to severe osteoarthritis of the knee

Vol: 2| Issue: 7| Number:229| ISSN#: 2564-2537
Study Type:Therapy
OE Level Evidence:2
Journal Level of Evidence:N/A

Preliminary assessment of the safety and efficacy of tanezumab in Japanese patients with moderate to severe osteoarthritis of the knee: A randomized, double-blind, dose-escalation, placebo-controlled study

Osteoarthritis Cartilage; 2011;19(12):1405-1412

Contributing Authors:
H Nagashima M Suzuki S Araki T Yamabe C Muto Tanezumab Investigatorsa

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here

Synopsis

83 Japanese patients with moderate to severe osteoarthritis of the knee were randomized to receive either tanezumab 10, 25, 50, 100 or 200 mg/kg or a placebo. The results from 120 day follow-up indicated that stronger doses of tanezumab result in significantly better pain relief in comparison to baseline measurements. However, the results from the study also indicated that adverse events occurred ...

CME Image

Did you know that you’re eligible to earn 0.5 CME credits for reading this report!

LEARN MORE

Join the Conversation

Please Login or Join to leave comments.

Learn about our AI Driven
High Impact Search Feature

High Impact Icon

Our AI driven High Impact metric calculates the impact an article will have by considering both the publishing journal and the content of the article itself. Built using the latest advances in natural language processing, OE High Impact predicts an article’s future number of citations better than impact factor alone.

Continue